神經病變診斷市場 - 全球產業規模、佔有率、趨勢、機會及預測（按產品、疾病、最終用戶、地區和競爭格局分類），2021-2031年

全球神經系統疾病診斷市場預計將從 2025 年的 109.1 億美元成長到 2031 年的 173.2 億美元，複合年成長率為 8.01%。

該領域涵蓋醫療行業，致力於開發用於識別和監測影響中樞和周圍神經系統病理的技術和檢測方法，例如神經影像系統和體外診斷測試。推動該市場成長要素是全球人口快速老化以及由此導致的慢性神經退化性疾病盛行率上升，進而催生了對精準早期療育工具的需求。最新數據顯示，阿茲海默症協會估計，到2025年，約有720萬65歲及以上的美國人將患有老年失智症失智症，這項數據也印證了疾病負擔日益加重的現狀。這項統計數據凸顯了對有效診斷能力的迫切需求和不斷成長的需求。

儘管臨床需求強勁，但先進診斷程序和設備的高成本是阻礙市場擴張的一大挑戰。診斷影像基礎設施所需的大量資金投入，加上許多發展中地區報銷體系的不完善，造成了經濟壁壘，限制了眾多病患的就醫途徑。因此，這些經濟限制阻礙了新興市場對綜合診斷解決方案的廣泛應用，對整個產業的成長軌跡產生了負面影響。

市場促進因素

全球神經系統疾病和神經退化性疾病盛行率的不斷上升是診斷市場的主要驅動力，也因此迫切需要可擴展的檢測解決方案。隨著中風和失智症等疾病的日益增多，醫療保健系統必須優先考慮早期檢測，以減輕疾病負擔。近期一項分析強調了這一人口結構變化，該分析預測，根據2024年3月發表於《柳葉刀神經病學》的《2021年全球疾病負擔研究》，全球將有約34億人患有神經系統疾病。如此廣泛的盛行率意味著巨大的經濟負擔，促使人們採用各種工具進行及時干預。阿茲海默症協會預測，到2024年，美國用於治療阿茲海默症和其他失智症患者的總成本將達到3,600億美元，這進一步凸顯了有效診斷能力的重要性，也進一步強調了這項經濟負擔的嚴重性。

神經影像和診斷方法的技術進步正透過提高準確性和可及性來重塑市場格局。生物標記分析的創新為資本密集掃描提供了非侵入性替代方案，有效降低了進入門檻。整合高精度檢測方法對於準確排除病理至關重要。例如，羅氏公司於2024年10月宣布，在阿茲海默症臨床試驗大會上發表的數據顯示，Elexis澱粉樣蛋白血漿檢測板在一項前瞻性研究中展現出96.2%的陰性預測值。這些進步提供了經濟高效的解決方案，克服了傳統神經影像技術的基礎設施限制，簡化了患者分層流程，並加速了市場普及。

市場挑戰

先進診斷程序和設備的高昂資金需求嚴重限制了神經系統疾病診斷市場的成長。醫療機構往往面臨磁振造影(MRI) 和電腦斷層掃描 (CT) 系統等關鍵基礎設施的高昂購置和維修成本。尤其是在發展中地區，不完善的報銷體係常常加劇了這種經濟負擔。這些經濟因素迫使許多醫療機構放棄購買或升級最新的診斷工具，導致市場滲透率停滯不前，並減少了為更廣泛的患者群體提供早期檢測服務的機會。

神經系統疾病對醫療保健系統帶來的巨大經濟壓力進一步限制了昂貴診斷檢測的資金投入。根據阿茲海默症協會預測，到2024年，全美用於治療阿茲海默症和其他失智症患者的總費用預計將達到3,600億美元。如此龐大的財政負擔造成了預算限制，往往導致高成本的影像和檢測技術無法覆蓋。因此，高成本造成了一種限制性環境，阻礙了綜合診斷解決方案的廣泛應用，從而對行業發展產生了負面影響。

市場趨勢

整合人工智慧 (AI) 和機器學習的自動化影像分析技術正在從根本上改變診斷格局，顯著提升複雜神經影像資料的解讀速度和準確性。這些演算法有助於自動分割病理觀察，例如白質病變和澱粉樣蛋白沉積，從而幫助解決臨床醫生職業倦怠和降低診斷差異等重大挑戰。這一趨勢正在迅速商業化，相關軟體獲得監管部門核准的數量不斷增加便印證了這一點。根據通用電氣醫療集團 (GE Healthcare) 2025 年 7 月發布的題為「GE Healthcare 透過投資人工智慧驅動的醫療設備推動成長」的新聞稿，該公司報告稱，迄今已獲得 100 項核准，位居美國食品藥品監督管理局 (FDA) 批准的人工智慧驅動醫療設備榜首，這反映出大規模推動自動化診斷支援系統的發展。

攜帶式照護現場神經系統評估的範圍從傳統的放射科擴展到加護病房和急診。借助低場磁振造影和緊湊型硬體，醫護人員可以進行床邊掃描，用於診斷中風和腦損傷，從而避免將病情不穩定的患者轉運至中心影像中心的風險。這種普及應用也得益於對緊湊型系統在急診環境中臨床有效性的持續檢驗。根據Hyperfine公司2024年12月發布的題為「Hyperfine在2024年北美放射學會年會上公佈大量臨床研究結果」的新聞稿，華盛頓大學醫學院一項值得關注的研究展示了使用攜帶式Swoop系統進行的350多例檢查的數據，證明了該系統在常規神經重症監護工作中日益成長的效用。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球神經病變診斷市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品（影像診斷、體外診斷）
  • 依疾病分類（遺傳性神經系統疾病、免疫介導性神經系統疾病、副腫瘤症候群、副蛋白神經病變）
  • 依最終使用者（醫院/專科診所、診斷中心、門診中心）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美神經病變診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲神經病變診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區神經病變診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲神經病變診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲神經病變診斷市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球神經病變診斷市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Siemens Healthineers AG
• Koninklijke Philips NV
• Esaote SPA
• NeuroLogica Corp.
• Masimo Corp
• Neusoft Corporation
• CANON MEDICAL SYSTEMS CORPORATION
• Abbott Laboratories Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Neurological Disorder Diagnostics Market is projected to expand from USD 10.91 Billion in 2025 to USD 17.32 Billion by 2031, reflecting a compound annual growth rate of 8.01%. This sector encompasses the medical industry dedicated to developing technologies and tests, including neuroimaging systems and in vitro assays, intended to identify and monitor pathologies affecting the central and peripheral nervous systems. The market is primarily driven by a rapidly aging global population and a concurrent rise in the prevalence of chronic neurodegenerative diseases, which create a critical need for precise early intervention tools. This growing disease burden is supported by recent data; according to the Alzheimer's Association, an estimated 7.2 million Americans aged 65 and older are living with Alzheimer's dementia in 2025, a statistic that underscores the urgent and escalating demand for effective diagnostic capabilities.

Despite the strong clinical necessity, a significant challenge hindering market expansion is the high cost associated with advanced diagnostic procedures and equipment. The substantial capital required for imaging infrastructure, combined with inadequate reimbursement frameworks in many developing regions, creates a financial barrier that limits accessibility for a large patient demographic. Consequently, these economic constraints restrict the widespread adoption of comprehensive diagnostic solutions in emerging markets and negatively impact the overall growth trajectory of the industry.

Market Driver

The rising global prevalence of neurological and neurodegenerative disorders serves as the primary catalyst for the diagnostics market, creating an urgent imperative for scalable testing solutions. As conditions such as stroke and dementia accelerate, healthcare systems must prioritize early identification to mitigate the compounding burden. This demographic shift is highlighted by recent analysis; according to The Lancet Neurology in the 'Global Burden of Disease Study 2021', published in March 2024, approximately 3.4 billion individuals globally were living with a neurological condition. This pervasive morbidity translates into immense financial strain, driving the adoption of tools for timely intervention. Underscoring this economic weight, according to the Alzheimer's Association, the total cost for caring for people with Alzheimer's and other dementias in the United States was projected to reach $360 billion in 2024, reinforcing the need for effective diagnostic capabilities.

Technological breakthroughs in neuroimaging and diagnostic modalities are simultaneously reshaping the market by enhancing precision and accessibility. Innovations in biomarker profiling now offer non-invasive alternatives to capital-intensive scans, effectively reducing adoption barriers. The integration of high-performance assays is pivotal for accurately ruling out pathologies. For instance, according to Roche in October 2024, data presented at the 'Clinical Trials in Alzheimer's Disease' congress showed that the Elecsys Amyloid Plasma Panel demonstrated a negative predictive value of 96.2% in a prospective study. Such advancements streamline patient stratification and encourage market uptake by offering cost-effective solutions that address the infrastructural limitations of traditional neuroimaging.

Market Challenge

The substantial capital required for advanced diagnostic procedures and equipment presents a significant barrier to the growth of the neurological disorder diagnostics market. Healthcare providers often face high acquisition and maintenance costs for essential infrastructure, such as magnetic resonance imaging and computed tomography systems. This financial burden is frequently compounded by inadequate reimbursement structures, particularly in developing regions. These economic factors effectively prevent many medical facilities from purchasing or upgrading to modern diagnostic tools, thereby stalling market penetration and reducing the availability of early detection services for a wide demographic of patients.

The immense economic pressure placed on healthcare systems by neurological conditions further restricts the allocation of funds toward expensive diagnostic testing. According to the Alzheimer's Association, the total national cost of caring for individuals with Alzheimer's and other dementias was projected to reach $360 billion in 2024. This staggering financial obligation forces budget constraints that often limit coverage for high-cost imaging and assay technologies. Consequently, the high cost of care creates a restrictive environment that hampers the widespread adoption of comprehensive diagnostic solutions and negatively impacts industry expansion.

Market Trends

The integration of Artificial Intelligence and Machine Learning for automated image analysis is fundamentally altering the diagnostic landscape by enhancing the speed and accuracy of interpreting complex neuroimaging data. These algorithms assist radiologists by automating the segmentation of pathological findings, such as white matter lesions or amyloid burden, thereby addressing the critical issue of clinician burnout and reducing diagnostic variability. This trend is rapidly commercializing, as evidenced by the increasing regulatory approval of such software. According to GE HealthCare in a July 2025 press release titled 'GE HealthCare drives growth with investment in AI-enabled medical devices', the company reported topping the FDA's list of AI-enabled medical device authorizations with 100 clearances to date, reflecting the massive industry push toward automated diagnostic support systems.

The shift towards portable and point-of-care diagnostic devices is expanding the reach of neurological assessment beyond traditional radiology suites into critical care units and emergency departments. By utilizing low-field magnetic resonance imaging and miniaturized hardware, providers can now perform bedside scans for stroke and brain injury, eliminating the risks associated with transporting unstable patients to central imaging facilities. This adoption is supported by growing clinical validation of these compact systems in acute settings. According to Hyperfine, Inc. in December 2024, in the press release 'Hyperfine Announces Extensive Clinical Study Coverage at RSNA 2024', a featured study from Washington University School of Medicine presented data from over 350 exams using the portable Swoop system, demonstrating its increasing utility in routine neurocritical care workflows.

Key Market Players

• Siemens Healthineers AG
• Koninklijke Philips N.V.
• Esaote SPA
• NeuroLogica Corp.
• Masimo Corp
• Neusoft Corporation
• CANON MEDICAL SYSTEMS CORPORATION
• Abbott Laboratories Inc

Report Scope

In this report, the Global Neurological Disorder Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neurological Disorder Diagnostics Market, By Product

• Imaging
• In Vitro Diagnostics

Neurological Disorder Diagnostics Market, By Disease Indication

• Genetic Neurological Disorders
• Immunological Neurological Disorders
• Paraneoplastic Syndrome
• Paraproteinemic Neuropathies

Neurological Disorder Diagnostics Market, By End User

• Hospitals and Specialty Clinics
• Diagnostic Centres
• Ambulatory Care Centers

Neurological Disorder Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neurological Disorder Diagnostics Market.

Available Customizations:

Global Neurological Disorder Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neurological Disorder Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Imaging, In Vitro Diagnostics)
  • 5.2.2. By Disease Indication (Genetic Neurological Disorders, Immunological Neurological Disorders, Paraneoplastic Syndrome, Paraproteinemic Neuropathies)
  • 5.2.3. By End User (Hospitals and Specialty Clinics, Diagnostic Centres, Ambulatory Care Centers)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Neurological Disorder Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Disease Indication
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Neurological Disorder Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Disease Indication
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Neurological Disorder Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Disease Indication
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Neurological Disorder Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Disease Indication
      • 6.3.3.2.3. By End User

7. Europe Neurological Disorder Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Disease Indication
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Neurological Disorder Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Disease Indication
      • 7.3.1.2.3. By End User
  • 7.3.2. France Neurological Disorder Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Disease Indication
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Neurological Disorder Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Disease Indication
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Neurological Disorder Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Disease Indication
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Neurological Disorder Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Disease Indication
      • 7.3.5.2.3. By End User

8. Asia Pacific Neurological Disorder Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Disease Indication
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Neurological Disorder Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Disease Indication
      • 8.3.1.2.3. By End User
  • 8.3.2. India Neurological Disorder Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Disease Indication
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Neurological Disorder Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Disease Indication
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Neurological Disorder Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Disease Indication
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Neurological Disorder Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Disease Indication
      • 8.3.5.2.3. By End User

9. Middle East & Africa Neurological Disorder Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Disease Indication
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Neurological Disorder Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Disease Indication
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Neurological Disorder Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Disease Indication
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Neurological Disorder Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Disease Indication
      • 9.3.3.2.3. By End User

10. South America Neurological Disorder Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Disease Indication
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Neurological Disorder Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Disease Indication
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Neurological Disorder Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Disease Indication
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Neurological Disorder Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Disease Indication
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Neurological Disorder Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Siemens Healthineers AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Koninklijke Philips N.V.
• 15.3. Esaote SPA
• 15.4. NeuroLogica Corp.
• 15.5. Masimo Corp
• 15.6. Neusoft Corporation
• 15.7. CANON MEDICAL SYSTEMS CORPORATION
• 15.8. Abbott Laboratories Inc

16. Strategic Recommendations

17. About Us & Disclaimer